Gastric Cancer, Version 2.2013

Ajani, Jaffer A.; Bentrem, David J.; Besh, Stephen; D’Amico, Thomas A.; Das, Prajnan; Denlinger, Crystal S.; Fakih, Marwan; Fuchs, Charles S.; Gerdes, Hans; Glasgow, Robert E.; Hayman, James A.; Hofstetter, Wayne L.; Ilson, David H.; Keswani, Rajesh N.; Kleinberg, Lawrence; Korn, W. Michael; Lockhart, A. Craig; Meredith, Kenneth; Mulcahy, Mary F.; Orringer, Mark B.; Posey, James; Sasson, Aaron R.; Scott, Walter J.; Strong, Vivian E.; Varghese, Thomas K.; Warren, Graham; Washington, Mary Kay; Willett, Christopher G.; Wright, Cameron D.; McMillian, Nicole R.; Sundar, Hema

doi:10.6004/jnccn.2013.0070

Cited by 416 publications

(187 citation statements)

References 44 publications

Supporting

Mentioning

186

Contrasting

Unclassified

Order By: Relevance

“…31 and gastric malignancies. 32,33 IHC and/or FISH results were both used to classify each tumor as HER2 amplified or nonamplified in accordance with the standard practice at our institution; IHC was performed first on all specimens, and only equivocal cases were reflexed to FISH. If there was a discordance between the IHC and the NGS result, FISH was performed when material was available.…”

Section: Case Selection and Standard Her2 Testingmentioning

confidence: 99%

Next-Generation Assessment of Human Epidermal Growth Factor Receptor 2 (ERBB2) Amplification Status

Ross

Zehir

Cheng

et al. 2017

The Journal of Molecular Diagnostics

View full text Add to dashboard Cite

The ASCP designates this journal-based CME activity ("JMD 2017 CME Program in Molecular Diagnostics") for a maximum of 36 AMA PRA Category 1 Credit(s)ä. Physicians should only claim credit commensurate with the extent of their participation in the activity. CME Disclosures: The authors of this article and the planning committee members and staff have no relevant financial relationships with commercial interests to disclose. Establishing ERBB2 [human epidermal growth factor receptor 2 (HER2)] amplification status in breast and gastric carcinomas is essential to treatment selection. Immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) constitute the current standard for assessment. With further advancements in genomic medicine, new clinically relevant biomarkers are rapidly emerging and options for targeted therapy are increasing in patients with advanced disease, driving the need for comprehensive molecular profiling. Nextgeneration sequencing (NGS) is an attractive approach for up-front comprehensive assessment, including ERBB2 status, but the concordance with traditional methods of HER2 assessment is not well established. The Memorial Sloan KetteringeIntegrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT) assay, a hybrid capture-based NGS assay interrogating the coding regions of 410 cancer-related genes, was performed on manually macrodissected unstained sections from formalin-fixed, paraffin-embedded breast (n Z 213) and gastroesophageal (n Z 39) tumors submitted for clinical mutation profiling. ERBB2 status was assessed using a custom bioinformatics pipeline, and NGS results were compared to IHC and FISH. NGS ERBB2 amplification calls had an overall concordance of 98.4% (248/252) with the combined IHC/FISH results in this validation set. Discrepancies occurred in the context of low tumor content and HER2 heterogeneity. ERBB2 amplification status can be reliably determined by hybridization capture-based NGS methods, allowing efficient concurrent testing for other potentially actionable genomic alterations, particularly in limited material. (J Mol Diagn 2017, 19: 244e254; http://dx.doi.org/10.1016/j.jmoldx.2016 Human epidermal growth factor receptor 2 (HER2) is a 185-kDa transmembrane tyrosine kinase receptor encoded by the ERBB2 gene (chromosome 17q12) that is a biomarker and therapeutic target in patients with breast and gastric cancers. Approximately 18% to 25% 1e3 of all breast and 15% to 30% 4e8 of all gastric or gastroesophageal (GE) cancers are classified as HER2-positive as a result of ERBB2 gene amplification and the subsequent overexpression of the HER2 protein on the surface of tumor cells. Therapies targeting HER2 have been approved for clinical use and include HER2-directed humanized monoclonal antibodies (ie, trastuzumab and pertuzumab) and small-molecule HER2 kinase inhibitors (ie, lapatinib).In breast cancer, HER2 is both a predictive and prognostic biomarker. HER2-positive status predicts response to HER2-targeted therapy, and multiple prospective randomized...

show abstract

Section: Case Selection and Standard Her2 Testingmentioning

confidence: 99%

Next-Generation Assessment of Human Epidermal Growth Factor Receptor 2 (ERBB2) Amplification Status

Ross

Zehir

Cheng

et al. 2017

The Journal of Molecular Diagnostics

View full text Add to dashboard Cite

show abstract

“…Therefore, surveillance for early detection of extragastric recurrence and curative surgery in cases of regional lymph node recurrence should be recommended after endoscopic treatment of EGC. Although the value of postoperative surveillance remains controversial [29][30][31], major guidelines recommend regular and systematic follow-up with endoscopy and cross-sectional imaging, and many cancer centers have established their own follow-up protocols after curative treatment that include these methods [2,32,33]. The role of endoscopy in surveillance after endoscopic resection has been proven in several studies, but its role is limited to the detection of intragastric recurrence [13][14][15].…”

Section: Discussionmentioning

confidence: 99%

Pattern of extragastric recurrence and the role of abdominal computed tomography in surveillance after endoscopic resection of early gastric cancer: Korean experiences

et al. 2017

View full text Add to dashboard Cite

Background Although extragastric recurrence after endoscopic resection of early gastric cancer is rare, it is important because of its potentially fatal outcomes. We investigated the patterns of extragastric recurrence after endoscopic resection and evaluated the role of abdominal computed tomography in surveillance. Methods Between July 1994 and June 2014, 4915 patients underwent endoscopic resection of early gastric cancer. Because of follow-up periods of less than 6 months and consecutive surgery within 1 year, 810 patients were excluded. Thus, 4105 patients were retrospectively reviewed. Results The median follow-up period was 37 months (interquartile range 20-59.6 months). The overall incidence of extragastric recurrence was 0.37% (n = 15). In patients who underwent curative resection, the incidence was 0.14% (n = 5). There were three recurrences in the absolute indication group, six in the expanded indication group, and six in the beyond expanded indication group. The median time to extragastric recurrence was 17 months (interquartile range 16.5-43.2 months). Of the 15 extragastric recurrences, 11 were in the regional lymph nodes and 4 were in the liver, adrenal gland, and peritoneum. Sixty percent (9/15) of the extragastric recurrences occurred without intragastric lesions. Eleven recurrences were detected by abdominal computed tomography, and eight patients underwent curative surgery. Conclusions After endoscopic resection of early gastric cancer, regional lymph node recurrence is the predominant extragastric recurrence pattern, which can be detected via abdominal computed tomography and cured by rescue surgery. Abdominal computed tomography should be considered as a surveillance method, especially in patients with an expanded indication.

show abstract

“…Postoperative treatments were focused on chemotherapy regimens and cycles, and radiotherapy if applicable. GC patients with T2 or higher, any N tumors should receive systemic chemotherapy except patients who declined the offer [15]. Hyperthermic intraperitoneal chemotherapy (HIPEC) and intraperitoneal chemotherapy (IP chemotherapy) were adjuvant chemotherapy, and only those who had peritoneal carcinomatosis (PC) should receive [16].…”

Section: Methodsmentioning

confidence: 99%

Long term follow up and retrospective study on 533 gastric cancer cases

Zeng

Wang

et al. 2014

BMC Surg

View full text Add to dashboard Cite

BackgroundGastric cancer (GC) is the third leading cause of cancer death in China and the outcome of GC patients is poor. The aim of the research is to study the prognostic factors of gastric cancer patients who had curative intent or palliative resection, completed clinical database and follow-up.MethodsThis retrospective study analyzed 533 GC patients from three tertiary referral teaching hospitals from January 2004 to December 2010 who had curative intent or palliative resection, complete clinical database and follow-up information. The GC-specific overall survival (OS) status was determined by the Kaplan-Meier method, and univariate analysis was conducted to identify possible factors for survival. Multivariate analysis using the Cox proportional hazard model and a forward regression procedure was conducted to define independent prognostic factors.ResultsBy the last follow-up, the median follow-up time of 533 GC patients was 38.6 mo (range 6.9-100.9 mo), and the median GC-specific OS was 25.3 mo (95% CI: 23.1-27.4 mo). The estimated 1-, 2-, 3- and 5-year GC-specific OS rates were 78.4%, 61.4%, 53.3% and 48.4%, respectively. Univariate analysis identified the following prognostic factors: hospital, age, gender, cancer site, surgery type, resection type, other organ resection, HIPEC, LN status, tumor invasion, distant metastases, TNM stage, postoperative SAE, systemic chemotherapy and IP chemotherapy. In multivariate analysis, seven factors were identified as independent prognostic factors for long term survival, including resection type, HIPEC, LN status, tumor invasion, distant metastases, postoperative SAE and systemic chemotherapy.ConclusionsResection type, HIPEC, postoperative SAE and systemic chemotherapy are four independent prognostic factors that could be intervened for GC patients for improving survival.

show abstract

Gastric Cancer, Version 2.2013

Cited by 416 publications

References 44 publications

Next-Generation Assessment of Human Epidermal Growth Factor Receptor 2 (ERBB2) Amplification Status

Next-Generation Assessment of Human Epidermal Growth Factor Receptor 2 (ERBB2) Amplification Status

Pattern of extragastric recurrence and the role of abdominal computed tomography in surveillance after endoscopic resection of early gastric cancer: Korean experiences

Long term follow up and retrospective study on 533 gastric cancer cases

Contact Info

Product

Resources

About